Blood test after surgery could spot hidden cancer cells
NCT ID NCT07268469
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a blood test for circulating tumor DNA (ctDNA) can detect leftover cancer after surgery in people with breast, lung, prostate, ovarian, or stomach cancer. About 840 participants will give blood samples before and after standard treatments. No new treatments are tested; the goal is to see how often ctDNA is found and if it relates to cancer returning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could show that ctDNA testing helps find remaining cancer cells earlier, pointing toward better monitoring strategies.
- What could go wrong
- This is an early observational study with no treatment given, so it won't directly improve outcomes. It may also fail to detect ctDNA in enough patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a new tracer light up hidden prostate cancer?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could deep breaths before surgery ward off Post-Op confusion?